Jury orders AbbVie to pay $140M+ for misrepresenting testosterone drug risks

AbbVie must pay more than $140 million to a Tennessee man who says he experienced a heart attack after taking the company's testosterone replacement drug AndroGel, a federal jury ruled Thursday, according to Reuters.

Here are four things to know.

1. Jeffrey Konrad and his wife filed the lawsuit against AbbVie in 2015. Mr. Konrad experienced a heart attack after taking AndroGel for two months in 2010.

2. The jury ruled AbbVie misrepresented the drug's risks and ordered the company to pay $140 million in punitive damages and $140,000 in compensatory damages, according to David Buchanan, an attorney for Mr. Konrad.

3. AbbVie contends it marketed AndroGel strictly for uses approved by the Food and Drug Administration.

"We are disappointed with today's verdict, and we intend to appeal," AbbVie said in a statement cited by Reuters.

4. AbbVie faces numerous lawsuits from plaintiffs across the country who claim AndroGel caused heart attacks, strokes and other injuries. In a separate federal trial in July, the jury also ruled AbbVie misrepresented the drug's risks and ordered the drugmaker to pay $150 million in punitive damages.

More articles on supply chain:

FDA approves first Zika blood screening test
J&J exits insulin pump business: 4 things to know
CVS rolls out medication management tool: 4 things to know

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars